New research has found that Cannnabidiol is active against Gram-positive bacteria, including those responsible for many serious infections (such as Staphyloccocus aureus and Streptococcus pneumoniae), with potency similar to that of established antibiotics such as vancomycin or daptomycin.
The research is presented at ASM Microbe, the annual meeting of the American Society for Microbiology.
Cannabidiol, the main non-psychoactive chemical compound extracted from cannabis and hemp plants, has been approved by FDA for the treatment of a form of epilepsy, and is being investigated for a number of other medical conditions, including, anxiety, pain and inflammation. While there is limited data to suggest Cannabidiol can kill bacteria, the drug has not been thoroughly investigated for its potential as an antibiotic.
Work led by Dr Mark Blaskovich at The University of Queensland’s Institute for Molecular Bioscience’s Centre for Superbug Solutions, in collaboration with Botanix Pharmaceuticals Ltd, an early stage drug discovery company investigating topical uses of synthetic cannabidiol for a range of skin conditions, found that Cannabidiol was remarkably effective at killing a wide range of Gram-positive bacteria, including bacteria that have become resistant to other antibiotics, and did not lose effectiveness after extended treatment.
“Given cannabidiol’s documented anti-inflammatory effects, existing safety data in humans, and potential for varied delivery routes, it is a promising new antibiotic worth further investigation,” said Dr. Blaskovich. “The combination of inherent antimicrobial activity and potential to reduce damage caused by the inflammatory response to infections is particularly attractive.”
Importantly, the drug retained its activity against bacteria that have become highly resistant to other common antibiotics. Under extended exposure conditions that lead to resistance against vancomycin or daptomycin, Cannabidiol did not lose effectiveness. Cannabidiol was also effective at disrupting biofilms, a physical form of bacteria growth that leads to difficult-to-treat infections.
The project was co-funded by Botanix and Innovation Connections, an Australian government grant scheme to commercialize new products, processes and services. The paper will be presented on Sunday June 23rd from 11am-1 pm at the annual conference of the American Society for Microbiology, ASM Microbe 2019, at the Moscone Convention Center in San Francisco.
Learn more: Cannabidiol is a Powerful New Antibiotic
The Latest on: Cannnabidiol
via Google News
The Latest on: Cannnabidiol
- Cardiol Therapeutics Announces Topline Results from Phase I Single and Multiple Ascending Dose Clinical Trial of CardiolRxon April 12, 2021 at 5:56 am
“As our study represents one of the most comprehensive Phase I clinical trials ever conducted in adults with a pharmaceutically produced cannabidiol formulation, we are pleased that the data are ...
- Cardiol Therapeutics says CardiolRx safe and well tolerated in Phase I study of oral cannabidiol formulationon April 12, 2021 at 5:31 am
The biotechnology company said the results from the single and multiple ascending dose trial indicate that the drug was safe and well-tolerated at ...
- Cardiol Therapeutics Announces Topline Results from Phase I Single and Multiple Ascending Dose Clinical Trial of CardiolRx(TM)on April 12, 2021 at 4:41 am
Serial blood samples were taken to measure the level of cannabidiol and its two main metabolites. Story continues Topline results demonstrated that CardiolRx was safe and generally well tolerated ...
- Scottish CBD health products firm gets cash injection from hundreds of investorson April 12, 2021 at 1:22 am
Voyager, which was set up to supply high-quality cannabidiol (CBD) and hemp seed oil products, said it had raised almost five times its initial crowdfunding target of £175,000. It follows February’s ...
- Possible actions of cannabidiol in obsessive-compulsive disorder by targeting the WNT/β-catenin pathwayon April 9, 2021 at 9:57 am
Research for new treatment is mandatory. This review focuses on the potential effects of cannabidiol (CBD), as a potential therapeutic strategy, on OCD and some of the presumed mechanisms by which CBD ...
- cbdMD Partners with 2018 Masters Champion and #7 Ranked Golfer in the World, Patrick Reedon April 8, 2021 at 6:01 am
cbdMD, Inc. (NYSE American: YCBD, YCBDpA) (the “Company”), one of the leading and most highly trusted and recognized cannabidiol (CBD) brands, announced today that it has signed an exclusive CBD ...
- Global Cannabidiol Oil (CBD Oil) Market 2021 Major Players, Competitive Spectrum, Revenue Share and Sales Projections by 2026on April 4, 2021 at 10:51 pm
Apr 05, 2021 (CDN Newswire via Comtex) -- MarketandResearch.biz proclaims the addition of a new report titled Global Cannabidiol Oil (CBD Oil) Market Growth 2021-2026 offers broad insights extracted ...
- Global Cannabidiol(CBD) Water Market 2021 Key Drivers and Challenges, Opportunities and Forecast Insights by 2026on April 4, 2021 at 8:45 pm
The report entitled Global Cannabidiol (CBD) Water Market Growth 2021-2026 eases the process of understanding the essential product segments and their development. The report envelops the information ...
- Can Cannabidiol Interact With Standard Prescription Drugs?on April 3, 2021 at 5:00 pm
To view the original article, click here. Cannabidiol has little to no side effects and several positive effects. It can help people to cope with many different medical conditions and their symptoms.
- Cannabidiol Shop Launches High-Quality CBD Products to Offer Relief From Pain, Anxiety and Stresson March 29, 2021 at 9:30 am
March 29, 2021 - With many people suffering from different variations of pain, anxiety, and stress, the team at Cannabidiol Shop has introduced a range of CBD products, offers, and information at ...
via Bing News